Related Experiment Videos
Prostate-specific antigen: current status
1Clinics of Urology, 3rd Medical Faculty, Charles University, Prague, Czech Republic.
Folia Biologica
|April 26, 2001
Summary
Prostate-Specific Antigen (PSA) is crucial for managing prostate disease and early cancer detection. New methods aim to improve PSA test accuracy, addressing limitations in the diagnostic gray zone for better prostate cancer identification.
Area of Science:
- Urology
- Oncology
- Biochemistry
Background:
- Prostate-Specific Antigen (PSA) is a vital tumor marker in managing male prostatic diseases.
- Early detection of prostate cancer, a common neoplasm, heavily relies on PSA.
- Current PSA screening faces challenges, particularly low specificity in the 4-10 ng/ml range.
Purpose of the Study:
- To review the molecular forms and characteristics of PSA.
- To discuss factors affecting serum PSA concentrations and screening issues.
- To evaluate methods for enhancing PSA test sensitivity and specificity in prostate cancer detection.
Main Methods:
- Analysis of PSA molecular forms and influencing factors.
- Evaluation of diagnostic gray zone limitations (4-10 ng/ml).
- Assessment of advanced detection techniques: PSA density, transition zone PSA density, PSA velocity, PSA doubling time, age-specific PSA, free PSA, and RT-PCR.
Main Results:
- PSA is essential for prostate cancer management and early detection.
- Low specificity of PSA in the 4-10 ng/ml range presents a diagnostic challenge.
- Various methods show potential to improve PSA test accuracy.
Conclusions:
- PSA remains a cornerstone in prostate cancer diagnostics.
- Improving PSA specificity is critical for accurate diagnosis.
- Advanced techniques offer promising avenues for more precise prostate cancer detection.